Insider Worth Mentioning: The Insider Lisa Bright Unloaded 249 shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

November 30, 2016 - By whatsonthorold

Insider Worth Mentioning: The Insider Lisa Bright Unloaded 249 shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

Lisa Bright Insider Sell

An insider Lisa Bright who is President International of Intercept Pharmaceuticals Inc unloaded some 249 shares of the Pinksheet-listed company valued at near $28,286 USD at an average $113.6 per each share. In the last 30 days, she also sold 140 shares that are worth $15,718 USD. The filing was disclosed in a filing dated 29-11-2016 with the SEC. This trade decreased her ownership of the company to 0.08% total market cap or 18,209 shares.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Ratings Coverage

Out of 16 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 9 rate it a “Buy”, 4 “Sell”, while 3 “Hold”. This means 56% are positive. $423 is the highest target while $58 is the lowest. The $186.14 average target is 78.21% above today’s ($104.45) stock price. Intercept Pharmaceuticals has been the topic of 25 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by Wedbush on Wednesday, June 1. As per Tuesday, May 31, the company rating was maintained by Morgan Stanley. As per Wednesday, March 30, the company rating was initiated by Credit Suisse. The stock of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has “Neutral” rating given on Wednesday, March 30 by Goldman Sachs. The firm has “Outperform” rating by Cowen & Co given on Tuesday, May 31. The stock of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has “Underperform” rating given on Wednesday, October 28 by Bank of America. The stock of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) earned “Sell” rating by Cantor Fitzgerald on Wednesday, July 6. The rating was initiated by Wells Fargo with “Market Perform” on Friday, December 4. FBR Capital maintained Intercept Pharmaceuticals Inc (NASDAQ:ICPT) on Wednesday, November 11 with “Mkt Perform” rating. The stock of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) earned “Strong-Buy” rating by Vetr on Tuesday, September 22.

Insitutional Activity: The institutional sentiment increased to 1.22 in 2016 Q2. Its up 0.07, from 1.15 in 2016Q1. The ratio increased, as 32 funds sold all Intercept Pharmaceuticals Inc shares owned while 43 reduced positions. 28 funds bought stakes while 58 increased positions. They now own 20.08 million shares or 7.50% more from 18.68 million shares in 2016Q1.

The Massachusetts-based State Street has invested 0.01% in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). Credit Suisse Ag accumulated 83,640 shares or 0.01% of the stock. Marshall Wace Ltd Liability Partnership accumulated 109,127 shares or 0.13% of the stock. The New York-based Ghost Tree Ltd Limited Liability Company has invested 0.52% in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). State Common Retirement Fund has 0.01% invested in the company for 39,000 shares. Blackrock accumulated 2,143 shares or 0% of the stock. The California-based Checchi Cap Advisers has invested 0% in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). Profund Advisors Limited Com holds 0.07% of its portfolio in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) for 9,446 shares. National Planning Corp holds 0.67% or 50,835 shares in its portfolio. Janney Montgomery Scott Ltd Liability Corporation has 0.01% invested in the company for 3,231 shares. Rtw Invests Ltd Liability holds 1.93% of its portfolio in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) for 39,500 shares. Bancorporation Of Montreal Can holds 0% of its portfolio in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) for 11,434 shares. Fmr Ltd Liability holds 0.07% or 3.69M shares in its portfolio. Polar Capital Ltd Liability Partnership last reported 21,869 shares in the company. Axa holds 0.05% of its portfolio in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) for 83,363 shares.

Insider Transactions: Since July 5, 2016, the stock had 0 buys, and 16 sales for $7.11 million net activity. Shares for $25,296 were sold by Bright Lisa. The insider Shapiro David sold $246,733. $115,056 worth of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) shares were sold by Pruzanski Mark. Another trade for 146 shares valued at $21,186 was sold by Duncan Barbara Gayle. 106 shares were sold by McMinn Rachel, worth $15,382.

The stock decreased 3.92% or $4.26 during the last trading session, hitting $104.45. About 513,942 shares traded hands or 4.17% up from the average. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has declined 26.69% since April 26, 2016 and is downtrending. It has underperformed by 31.95% the S&P500.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $2.43 billion. The Firm is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. It currently has negative earnings. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

According to Zacks Investment Research, “Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company’s lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC). Intercept Pharmaceuticals Inc. is headquartered in New York.”

Analysts await Intercept Pharmaceuticals Inc (NASDAQ:ICPT) to report earnings on February, 28. They expect $-3.62 EPS, 0.00% or $0.00 from last year’s $-3.62 per share. After $-3.59 actual EPS reported by Intercept Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 0.84% negative EPS growth.

More news for Intercept Pharmaceuticals Inc (NASDAQ:ICPT) were recently published by: Investorplace.com, which released: “Charles Payne on Biotech: Biogen Inc (BIIB), Intercept Pharmaceuticals Inc (ICPT)” on November 29, 2016. Fool.com‘s article titled: “Why Intercept Pharmaceuticals Inc is Skyrocketing Today” and published on February 12, 2016 is yet another important article.

ICPT Company Profile

Intercept Pharmaceuticals, Inc., incorporated on September 4, 2002, is a biopharmaceutical company. The Firm is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Firm is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>